Search results for "Digest"

showing 10 items of 3038 documents

Chronic hepatitis B: Do we know everything or is there still something to learn?

2009

Chronic hepatitis B is a dynamic process with different phases. The progression of liver damage is related to time of infection, linked to the persistence of viral replication, and based on the virus–host interaction. [1]. The course of liver disease can be modified by virological events related to the kinetics of HBV replication and influenced by the host immune system. Knowledge of the natural history of HBV infection and of its viral replication mechanisms suggest the treatment end points and guide the choice of antiviral drugs [2–4]. The key points for the management of chronic hepatitis Ba re: Evaluation of viral status (HBeAg positive or HBeAg negative), staging of liver disease (chro…

Hepatitis B virusHBsAgCirrhosisHepatologybusiness.industryGastroenterologyvirus diseasesmedicine.diseasemedicine.disease_causedigestive system diseasesLiver diseaseViral replicationHBeAgHepatocellular carcinomaImmunologymedicinebusinessViral loadDigestive and Liver Disease Supplements
researchProduct

Ligase Chain Reaction (LCR®) assay for semi-quantitative detection of HBV DNA in mononuclear leukocytes of patients with chronic hepatitis B

1996

Summary. A ligase chain reaction (LCR®)-based approach to detect hepatitis B virus (HBV) DNA in peripheral blood mononuclear cells (PBMC) is described. Using this new amplification technique, we determined semi-quantitatively the amount of a short HBV S-gene fragment in PBMC lysates of 25 patients with different forms of chronic hepatitis (group A (n= 8), hepatitis B s antigen (HBsAg)+/hepatitis B e antigen (HBeAg)+; group B (n= 9), HBsAg+/HBeAg-; group C (n= 8), HBsAg-/HBeAg-). The LCR results were compared with the findings obtained with polymerase chain reaction (PCR) amplification of three distinct HBV gene regions (preS1/2, S and C) and related to the serological profiles of the patien…

Hepatitis B virusHBsAgHepatitis B virus DNA polymerasemedicine.disease_causePolymerase Chain ReactionSensitivity and Specificitylaw.inventionLigaseslawVirologymedicineHumansHepatitis B e AntigensLigase chain reactionPolymerase chain reactionHepatitis B virusHepatitis B Surface AntigensHepatologyClinical Laboratory Techniquesbusiness.industryvirus diseasesHepatitis BHepatitis Bmedicine.diseaseVirologyMolecular biologydigestive system diseasesInfectious DiseasesHBeAgDNA ViralLeukocytes MononuclearPrimer (molecular biology)business
researchProduct

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of thein vit…

1999

Because cellular and humoral immune responses against the hepatitis B virus (HBV) surface antigen (HBs) might be crucial to overcome HBV infection, HBs-specific B- and T-cell responses of HBV patients and HBs vaccine recipients were analyzed quantitatively and functionally. In patients with acute hepatitis B (AHB), transient high anti-HBs-secreting B-cell frequencies were observed early after clinical onset, whereas 1 patient who probably developed chronic infection and chronic HBV carriers had absent or weak B- and T-cell responses. In HBs vaccine recipients, maximal HBs-specific B- and T-cell responses were detected after the first injection that decreased gradually before anti-HBs antibo…

Hepatitis B virusHBsAgHepatologybiologybusiness.industryvirus diseasesHepatitis Bmedicine.disease_causebiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesVaccinationHepadnaviridaeAntigenOrthohepadnavirusImmunologymedicinebiology.proteinAntibodybusinessHepatology
researchProduct

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B

2002

To evaluate therapeutic immunostimulation nine chronic hepatitis B patients received six monthly intradermal vaccinations with HBsAg in combination with daily lamivudine. Another five patients received six doses of the vaccine and daily lamivudine together with daily Interleukin-2 (IL-2) s.c. within 3 months in an open-labeled trial. Clinical efficacy was assessed by alanine transaminase levels and HBV serology. The induction of specific T and B cell responses was analyzed serially by 3H-thymidine uptake, ELISA and ELISPOT assays. After the therapy was stopped, seven of nine vaccine/lamivudine and two of five vaccine/lamivudine/IL-2 recipients did not have detectable HBV DNA. Four complete …

Hepatitis B virusHBsAgbiologybusiness.industryELISPOTLamivudineHepatitis Bmedicine.diseasemedicine.disease_causeVirologydigestive system diseasesVaccine therapyVaccinationInfectious DiseasesAlanine transaminaseVirologyImmunologymedicinebiology.proteinbusinessmedicine.drugJournal of Medical Virology
researchProduct

Endemic hepatitis C virus infection in a Sicilian town: Further evidence for iatrogenic transmission

2002

The prevalence of and risk factors for HCV and HBV infections in the general population and the predictive value of ALT screening in identifying anti-HCV positive subjects have been evaluated in a small Sicilian town. A random 1:4 sampling from the census of the general population was performed. Anti-HCV, HCV-RNA, HCV genotype, HBsAg, and anti-HBc were tested. The linkage between HCV infection and potential risk factors was evaluated by multiple logistic regression analysis. Among 721 subjects studied, 75 (10.4%) were anti-HCV positive. The HCV infection rate increased from 0.4% in subjects 10–29 years of age to 34% in those > 60 years of age. Among the 75 anti-HCV positive subjects, 66.7% …

Hepatitis B virusHBsAgeducation.field_of_studybusiness.industryIncidence (epidemiology)Populationvirus diseasesHepatitis CHepatitis Bmedicine.diseasemedicine.disease_causeVirologydigestive system diseasesInfectious DiseasesVirologyPredictive value of testsmedicineViral diseaseeducationbusinessJournal of Medical Virology
researchProduct

Treatment options in HBV.

2005

The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18). HBeAg positive patients with normal or slightly raised ALT should be treated only if there is histological evidence of progressive disease. In patients with HBeAg negative chronic hepatitis, less than 20% of subjects who have achieved an end-of-treatment virological response after a course of standard IFN maintain a sustained virological response in the long-term. IFN tre…

Hepatitis B virusHBsAgmedicine.medical_specialtyAdefovirmedicine.disease_causeAntiviral AgentsGastroenterologyHepatitis B AntigensLiver diseaseInternal medicineAdefovirHumansMedicineHepatitis B virusHepatologybusiness.industryvirus diseasesLamivudineHIVHepatitis Bmedicine.diseaseHepatitis Bdigestive system diseasesTreatmentTreatment OutcomeHBeAgLamivudineDNA ViralImmunologyNumber needed to treatInterferonbusinessLiver diseasemedicine.drug
researchProduct

Mutation specific PCR and direct solid phase sequencing assay for the detection of hepatitis B virus pre-C/C mutants in anti-HBe-positive, chronic he…

1994

Sequence analysis of the HBV DNA from patients with anti-HBe+, chronic hepatitis B revealed that the lack of HBeAg is mostly due to a single GA transition at nucleotide position 1896, resulting in a translational stop codon. A point mutation-specific polymerase chain reaction (msPCR) for the detection of this genetic variant was established. Two serologically defined groups of patients with symptomatic chronic hepatitis B (HBeAg+ n = 14, anti-HBe+ n = 11) were included in this study. Viral DNA from 43 sera (26 eAg+/17 anti-HBe+) was amplified twice, using two different sets of PCR primers. Each set contained the same — strand primer, but the + strand primers differed at their 3′-end, thus b…

Hepatitis B virusHepatitis B virus DNA polymeraseMolecular Sequence DataBiologymedicine.disease_causePolymerase Chain Reactionlaw.inventionlawVirologymedicineHumansPoint MutationHepatitis B e AntigensHepatitis B AntibodiesPolymerase chain reactionDNA PrimersHepatitis B virusBase SequencePoint mutationvirus diseasesGenetic Variationbiology.organism_classificationHepatitis BVirologyMolecular biologydigestive system diseasesStop codonInfectious DiseasesHepadnaviridaeHBeAgDNA ViralPrimer (molecular biology)Journal of medical virology
researchProduct

Stop codon insertion restores the particle formation ability of hepatitis B virus core-hantavirus nucleocapsid protein fusions.

2003

In recent years, epitopes of various origin have been inserted into the core protein of hepatitis B virus (HBc), allowing the formation of chimeric HBc particles. Although the C-terminus of a C-terminally truncated HBc (HBcΔ) tolerates the insertion of extended foreign sequences, the insertion capacity is still a limiting factor for the construction of multivalent vaccines. Previously, we described a new system to generate HBcΔ mosaic particles based on a read-through mechanism in an <i>Escherichia coli</i> suppressor strain [J Gen Virol 1997;78:2049–2053]. Those mosaic particles allowed the insertion of a 114-amino acid (aa)-long segment of a Puumala hantavirus (PUUV) nucleocap…

Hepatitis B virusHepatitis B virus DNA polymerasevirusesRecombinant Fusion ProteinsMolecular Sequence Datamedicine.disease_causeEpitopeHepatitis B virus PRE betaMiceVirologyparasitic diseasesmedicineAnimalsNucleocapsidHantavirusHepatitis B virusMice Inbred BALB CBase SequenceChemistryHepatitis B virus coreVirionvirus diseasesNucleocapsid ProteinsVirologyMolecular biologyHepatitis B Core Antigensdigestive system diseasesStop codonNS2-3 proteaseInfectious DiseasesCodon TerminatorImmunizationIntervirology
researchProduct

Virus replication and virion export in X-deficient hepatitis B virus transgenic mice

2002

The function of the X protein (pX) in the replication cycle of mammalian hepadnaviruses is enigmatic. Using tissue culture experiments it has been shown that the X gene product is not central to hepatitis B virus (HBV) replication and virion export. However, at present it is still unclear whether this also applies to the in vivo situation. Using a terminally redundant X-deficient HBV DNA construct, transgenic mice were established that exhibited high-level expression of the viral core protein in liver and kidneys. Importantly, replicative DNA intermediates and mature viral genomes could be detected in the liver and serum of these mice, respectively. These findings indicate that, in the in v…

Hepatitis B virusHepatitis B virus DNA polymerasevirusesTransgeneMice TransgenicBiologyVirus Replicationmedicine.disease_causeHepatitis B virus PRE betaGene productMicechemistry.chemical_compoundVirologymedicineAnimalsViral Regulatory and Accessory ProteinsHepatitis B virusVirionVirologyMolecular biologydigestive system diseasesMice Inbred C57BLHBxViral replicationchemistryMice Inbred DBATrans-ActivatorsDNAJournal of General Virology
researchProduct

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent

2003

The hepatitis B virus (HBV) core antigen (HBcAg) has a unique ability to bind a high frequency of naive human and murine B cells. The role of HBcAg-binding naive B cells in the immunogenicity of HBcAg is not clear. The HBcAg-binding properties of naive B cells were characterized using HBcAg particles with mutated spike region (residues 76-85) sequences. Deletion of residues 76-85 (HBcDelta76-85) destroyed naive B cell binding, whereas deletion of residues 79-85 did not. HBcAg particles with an Ile instead of the natural Ala at position 80 did not bind naive B cells, whereas reversion of Ile80--Ala restored B cell binding. Destroying the B cell-binding ability of HBcAg had a marginal effect …

Hepatitis B virusMolecular Sequence DataNaive B cellPriming (immunology)Biologymedicine.disease_causeMiceAntigenVirologymedicineAnimalsCytotoxic T cellHepatitis B VaccinesAmino Acid SequenceHepatitis B AntibodiesB cellHepatitis B virusB-LymphocytesVaccines SyntheticBinding SitesImmunogenicityVirionvirus diseasesHepatitis BHepatitis B Core AntigensVirologyRecombinant Proteinsdigestive system diseasesMice Inbred C57BLHBcAgmedicine.anatomical_structureImmunizationT-Lymphocytes Cytotoxic
researchProduct